1. Home
  2. BNKK vs LEXX Comparison

BNKK vs LEXX Comparison

Compare BNKK & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bonk Inc.

BNKK

Bonk Inc.

N/A

Current Price

$2.75

Market Cap

14.3M

ML Signal

N/A

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.99

Market Cap

16.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNKK
LEXX
Founded
2018
2004
Country
United States
Canada
Employees
8
7
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.3M
16.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BNKK
LEXX
Price
$2.75
$0.99
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
50.8K
182.0K
Earning Date
05-14-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.46
52 Week High
$7.19
$1.67

Technical Indicators

Market Signals
Indicator
BNKK
LEXX
Relative Strength Index (RSI) 51.46 60.14
Support Level $2.64 $0.80
Resistance Level $2.88 $1.05
Average True Range (ATR) 0.25 0.10
MACD 0.07 0.01
Stochastic Oscillator 71.85 76.31

Price Performance

Historical Comparison
BNKK
LEXX

About BNKK Bonk Inc.

Bonk Inc is a publicly traded company focused on building a digital asset treasury centered around the BONK ecosystem on the Solana blockchain. It generates revenue through a recurring interest in the memecoin launchpad letsBONK.fun and actively manages its treasury of BONK tokens.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: